1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lung Cancer Diagnostics Market Size Growth Rate by Type: 2018 VS 2022 VS 2030
1.2.2 Immunoassays
1.2.3 Flow Cytometry
1.2.4 Rapid Tests
1.2.5 Molecular Assays
1.2.6 Tissue Arrays
1.2.7 Circulating Tumor Cells
1.2.8 Pharmacodiagnostics
1.2.9 Biomarkers
1.2.10 Other
1.3 Market by Application
1.3.1 Global Lung Cancer Diagnostics Market Share by Application: 2018 VS 2022 VS 2030
1.3.2 Industrial
1.3.3 Healthcare
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Lung Cancer Diagnostics Market Perspective (2018-2030)
2.2 Lung Cancer Diagnostics Growth Trends by Region
2.2.1 Lung Cancer Diagnostics Market Size by Region: 2018 VS 2022 VS 2030
2.2.2 Lung Cancer Diagnostics Historic Market Size by Region (2018-2023)
2.2.3 Lung Cancer Diagnostics Forecasted Market Size by Region (2023-2030)
2.3 Lung Cancer Diagnostics Market Dynamics
2.3.1 Lung Cancer Diagnostics Industry Trends
2.3.2 Lung Cancer Diagnostics Market Drivers
2.3.3 Lung Cancer Diagnostics Market Challenges
2.3.4 Lung Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lung Cancer Diagnostics Players by Revenue
3.1.1 Global Top Lung Cancer Diagnostics Players by Revenue (2018-2023)
3.1.2 Global Lung Cancer Diagnostics Revenue Market Share by Players (2018-2023)
3.2 Global Lung Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Lung Cancer Diagnostics Revenue
3.4 Global Lung Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Lung Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lung Cancer Diagnostics Revenue in 2022
3.5 Lung Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Lung Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Lung Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Lung Cancer Diagnostics Breakdown Data by Type
4.1 Global Lung Cancer Diagnostics Historic Market Size by Type (2018-2023)
4.2 Global Lung Cancer Diagnostics Forecasted Market Size by Type (2023-2030)
5 Lung Cancer Diagnostics Breakdown Data by Application
5.1 Global Lung Cancer Diagnostics Historic Market Size by Application (2018-2023)
5.2 Global Lung Cancer Diagnostics Forecasted Market Size by Application (2023-2030)
6 North America
6.1 North America Lung Cancer Diagnostics Market Size (2018-2030)
6.2 North America Lung Cancer Diagnostics Market Size by Country (2018-2023)
6.3 North America Lung Cancer Diagnostics Market Size by Country (2023-2030)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Lung Cancer Diagnostics Market Size (2018-2030)
7.2 Europe Lung Cancer Diagnostics Market Size by Country (2018-2023)
7.3 Europe Lung Cancer Diagnostics Market Size by Country (2023-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lung Cancer Diagnostics Market Size (2018-2030)
8.2 Asia-Pacific Lung Cancer Diagnostics Market Size by Country (2018-2023)
8.3 Asia-Pacific Lung Cancer Diagnostics Market Size by Country (2023-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Lung Cancer Diagnostics Market Size (2018-2030)
9.2 Latin America Lung Cancer Diagnostics Market Size by Country (2018-2023)
9.3 Latin America Lung Cancer Diagnostics Market Size by Country (2023-2030)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lung Cancer Diagnostics Market Size (2018-2030)
10.2 Middle East & Africa Lung Cancer Diagnostics Market Size by Country (2018-2023)
10.3 Middle East & Africa Lung Cancer Diagnostics Market Size by Country (2023-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Roche Diagnostics
11.1.1 Roche Diagnostics Company Detail
11.1.2 Roche Diagnostics Business Overview
11.1.3 Roche Diagnostics Lung Cancer Diagnostics Introduction
11.1.4 Roche Diagnostics Revenue in Lung Cancer Diagnostics Business (2018-2023)
11.1.5 Roche Diagnostics Recent Development
11.2 BioM?rieux
11.2.1 BioM?rieux Company Detail
11.2.2 BioM?rieux Business Overview
11.2.3 BioM?rieux Lung Cancer Diagnostics Introduction
11.2.4 BioM?rieux Revenue in Lung Cancer Diagnostics Business (2018-2023)
11.2.5 BioM?rieux Recent Development
11.3 Qiagen
11.3.1 Qiagen Company Detail
11.3.2 Qiagen Business Overview
11.3.3 Qiagen Lung Cancer Diagnostics Introduction
11.3.4 Qiagen Revenue in Lung Cancer Diagnostics Business (2018-2023)
11.3.5 Qiagen Recent Development
11.4 Advpharma
11.4.1 Advpharma Company Detail
11.4.2 Advpharma Business Overview
11.4.3 Advpharma Lung Cancer Diagnostics Introduction
11.4.4 Advpharma Revenue in Lung Cancer Diagnostics Business (2018-2023)
11.4.5 Advpharma Recent Development
11.5 AIT Austrian Institute of Technology
11.5.1 AIT Austrian Institute of Technology Company Detail
11.5.2 AIT Austrian Institute of Technology Business Overview
11.5.3 AIT Austrian Institute of Technology Lung Cancer Diagnostics Introduction
11.5.4 AIT Austrian Institute of Technology Revenue in Lung Cancer Diagnostics Business (2018-2023)
11.5.5 AIT Austrian Institute of Technology Recent Development
11.6 Courtagen Life Sciences
11.6.1 Courtagen Life Sciences Company Detail
11.6.2 Courtagen Life Sciences Business Overview
11.6.3 Courtagen Life Sciences Lung Cancer Diagnostics Introduction
11.6.4 Courtagen Life Sciences Revenue in Lung Cancer Diagnostics Business (2018-2023)
11.6.5 Courtagen Life Sciences Recent Development
11.7 DiagnoCure
11.7.1 DiagnoCure Company Detail
11.7.2 DiagnoCure Business Overview
11.7.3 DiagnoCure Lung Cancer Diagnostics Introduction
11.7.4 DiagnoCure Revenue in Lung Cancer Diagnostics Business (2018-2023)
11.7.5 DiagnoCure Recent Development
11.8 BioMark Diagnostics
11.8.1 BioMark Diagnostics Company Detail
11.8.2 BioMark Diagnostics Business Overview
11.8.3 BioMark Diagnostics Lung Cancer Diagnostics Introduction
11.8.4 BioMark Diagnostics Revenue in Lung Cancer Diagnostics Business (2018-2023)
11.8.5 BioMark Diagnostics Recent Development
11.9 Mayo Clinic
11.9.1 Mayo Clinic Company Detail
11.9.2 Mayo Clinic Business Overview
11.9.3 Mayo Clinic Lung Cancer Diagnostics Introduction
11.9.4 Mayo Clinic Revenue in Lung Cancer Diagnostics Business (2018-2023)
11.9.5 Mayo Clinic Recent Development
11.10 HalioDx SAS
11.10.1 HalioDx SAS Company Detail
11.10.2 HalioDx SAS Business Overview
11.10.3 HalioDx SAS Lung Cancer Diagnostics Introduction
11.10.4 HalioDx SAS Revenue in Lung Cancer Diagnostics Business (2018-2023)
11.10.5 HalioDx SAS Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
